Consider a clinical trial for your patients who have early-stage resectable or locally advanced unresectable squamous or non-squamous non-small cell lung cancer (NSCLC). Connect with a clinical trial site to learn more and see if your patients may be eligible.

Symbiotic-Lung-10 is a Phase 2, open-label clinical trial evaluating the efficacy and safety of a study medicine, tivunatamig, as monotherapy or in combination chemotherapy in participants with early-stage resectable or locally advanced unresectable NSCLC.

There are 3 separate parts based on disease characteristics:

  • Resectable NSCLC
    • Part A (neoadjuvant): tivunatamig + chemotherapy, then surgery
    • Part B (adjuvant): tivunatamig monotherapy
  • Unresectable NSCLC
    • Part C (consolidation): tivunatamig monotherapy

For Parts B and C, participants may receive the study treatment until the maximum treatment duration is reached or sooner if the study doctor decides not to continue the study treatment.

After the study treatment ends, participants will have a follow-up visit or phone call every 12 weeks. For participants in Part A, follow-up begins after End of Treatment visit or recovery from surgery, whichever occurs later.

About the study medicine

The study medicine, tivunatamig, is a bispecific antibody drug that was designed to target both PD-1 and VEGF simultaneously. This dual mechanism has the potential to achieve tumor immunosurveillance, while disrupting vascular support for tumor progression, compared with blocking either of the targets alone in patients with solid tumors.

Preliminary clinical data with tivunatamig as a single agent1 and combined with chemotherapy2 shows encouraging results in patients with first-line NSCLC.

Key eligibility criteria

All parts

  • Aged 18 years or older
  • Squamous or non-squamous NSCLC
  • Cannot have EGFR and ALK AGAs

By part

  • Part A: Newly diagnosed, previously untreated Stage II or IIIA/B NSCLC that is considered resectable
  • Part B: Stage II or IIIA/B NSCLC and have undergone complete surgical resection after not achieving pCR on SOC neoadjuvant chemoimmunotherapy
  • Part C: Unresectable Stage III NSCLC and have received concurrent chemotherapy, resulting in no disease progression

AGAs, actionable genomic alterations; ALK, anaplastic lymphoma kinase; EGFR, epidermal growth factor receptor; pCR, pathological complete response.

Additional requirements apply. Only Principal Investigators can determine eligibility.

Study endpoints

Primary endpoints

  • Part A
    • Proportion of participants undergoing surgery
    • Proportion of participants with wound complications after surgery
    • pCR rate per IASLC guidelines as assessed by central pathology review
  • Parts A, B & C
    • AEs as characterized by type, frequency, severity as graded by NCI CTCAE v5.0, timing, seriousness, and relationship to study intervention

Key secondary endpoints

  • Part A
    • MPR rate per IASLC guidelines as assessed by central pathology review and by investigator
    • pCR rate per IASLC guidelines as assessed by investigator
    • EFS and ORR per RECIST v1.1 as assessed by investigator
    • Overall survival
  • Part B
    • DFS per RECIST v1.1 as assessed by investigator
    • Overall survival
  • Part C
    • Confirmed ORR and PFS per RECIST v1.1 as assessed by investigator
    • Overall survival

Safety endpoint (Parts A, B & C)

  • Laboratory abnormalities as characterized by type, frequency, severity as graded by NCI CTCAE v5.0

Note: This is not a complete list of study endpoints.

AE, adverse event; CTCAE, Common Terminology Criteria for Adverse Events; DFS, disease-free survival; EFS, event-free survival; IASLC, International Association for the Study of Lung Cancer; MPR, major pathological response; NCI, National Cancer Institute; ORR, objective response rate; PFS, progression-free survival; RECIST, Response Evaluation Criteria in Solid Tumors.

Together, we can make a difference

People are often introduced to clinical trials through conversations with their healthcare providers. We appreciate you taking the time to have discussions with your patients and their loved ones who may be interested in contributing to research.

Should any of your patients take part in this clinical trial, they will remain under your medical care for all non-study-related needs.

Thank you for considering your patients for this important clinical trial.

Is this page helpful?
References

1. Wu L, Yao J, Sun Y, et al. A phase II trial to evaluate the safety and efficacy of SSGJ-707, a bispecific antibody targeting PD-1 and VEGF, as a monotherapy in patients with advanced NSCLC. J Clin Oncol. 2025;43(suppl 16):8543. doi:10.1200/JCO.2025.43.16_suppl.8543

2. Wu L, Xu H, Sun Y, et al. 1328 SSGJ-707, a PD-1/VEGF bispecific antibody, combined with platinum-based chemotherapy in first-line treatment of advanced non-small cell lung cancer (NSCLC): Results from a phase 2 study. J Immunother Cancer. 2025;13(suppl 3):A1568-A1569. doi:10.1136/jitc-2025-SITC2025.1328